Patrick M Forde

30PUBLICATIONS
310CO-AUTHORS
Predictive and prognostic markersTumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (30)

|Jul 23, 2026
Landmark ctDNA molecular response represents an early predictor of immunotherapy outcomes in lung cancer: A clinical validity study.

|Apr 19, 2026
Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non-Small Cell Lung Cancer.

|Apr 19, 2026
plasmaCHORD: A Machine Learning Approach to Distinguish Clonal Hematopoiesis-Derived Variants in Liquid Biopsies from Patients with Solid Tumors.

|Sep 08, 2025
Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses.

Joshua E Reuss, Paul K Lee, Reza J Mehran

|Jun 02, 2025
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer.

Patrick M Forde, Jonathan D Spicer, Mariano Provencio

|May 31, 2025
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial.

Tina Cascone, Laura Bonanno, Florian Guisier

Pageof 5

Frequent Collaborators

17 joint publications

Valsamo Anagnostou

8 joint publications

Kellie N Smith

8 joint publications

Joseph Murray

7 joint publications

Julie R Brahmer